Company / Cash & Equivalents
NEKTAR THERAPEUTICS Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$15.1M
FY2025
5-year range
$15.1M / $88.2M
FY2021-FY2025
Trend
-65.8%
vs FY2024
Sector context
#202 of 207
Health Care
What the data says
Among 207 Health Care companies, NEKTAR THERAPEUTICS is in the bottom 2% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $5M in FY2017 to $199M in FY2020.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of -40.3%.
Declined from $35M to $15M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -44.5%
- 5-Year CAGR
- -40.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 207This company $15.1M Sector average $669.5M
▼
-97.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -40.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 65.8% year-over-year.
- Ranks #202 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.1M | -65.8% |
| FY2024 | $44.3M | +25.4% |
| FY2023 | $35.3M | -60.0% |
| FY2022 | $88.2M | +249.9% |
| FY2021 | $25.2M | -87.3% |
| FY2020 | $199.0M | +106.5% |
| FY2019 | $96.4M | -50.6% |
| FY2018 | $194.9M | +3992.9% |
| FY2017 | $4.8M | -61.5% |
| FY2016 | $12.4M | -77.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026